| Literature DB >> 11115719 |
G Leroux-Roels1, B Abraham, M Fourneau, N De Clercq, A Safary.
Abstract
The immunogenicity and reactogenicity profiles of three doses each of Engerix-B(R) (10 microg hepatitis B surface antigen) and Recombivax(R) (5 microg hepatitis B surface antigen), given on a 0, 1, 6 month schedule to healthy adolescents were compared in a single-blind, randomized clinical trial. One month following the third dose, seroprotection rates after Engerix-B and Recombivax were similar (99 and 98%, respectively). The geometric mean titre (GMT) was statistically significantly higher following vaccination with Engerix-B (3961 vs. 1001 mIU/ml; P=0.0001, Fisher's exact test). Most of the symptoms reported were mild or moderate in intensity and transient. There were no vaccine-related serious adverse events.Mesh：
Substances：
Year: 2000 PMID： 11115719 DOI： 10.1016/s0264-410x(00)00217-6
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641